HistoSonics Revenue and Competitors

Detroit, MI USA

Location

#1269

Growjo Ranking

Estimated Revenue & Valuation

  • HistoSonics's estimated annual revenue is currently $43.9M per year.(i)
  • HistoSonics's estimated revenue per employee is $313,750
  • HistoSonics's total funding is $126.8M.

Employee Data

  • HistoSonics has 140 Employees.(i)
  • HistoSonics grew their employee count by 21% last year.
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$30.6M122-1%N/AN/A
#2
$15.1M60-9%N/AN/A
#3
$18.1M726%N/AN/A
#4
$6M24-8%N/AN/A
#5
$75M2891%N/AN/A
#6
$12.3M499%N/AN/A
#7
$24.1M96-3%N/AN/A
#8
$0.3M1-75%N/AN/A
#9
$19.1M76-37%N/AN/A
#10
$6M24-11%N/AN/A
Add Company

HistoSonics is developing a non-invasive, autonomous robotic platform capable of destroying tissue at a sub-cellular level with a novel beam therapy and new medical procedure called Robotically Assisted Sonic Therapy (RAST)?. RAST is based on the science of histotripsy, a non-invasive, non-thermal and non-ionizing radiation modality developed at the University of Michigan that uses the pressure created by focused sound energy to completely ablate or destroy tissue at a sub-cellular level.

keywords:Biotechnology

$126.8M

Total Funding

140

Number of Employees

$43.9M

Revenue (est)

21%

Employee Growth %

N/A

Valuation

N/A

Accelerator

HistoSonics News

2022-04-17 - Tumors partially destroyed with sound don't come back

... of histotripsy in the fight against cancer, leading to the clinical trial #HOPE4LIVER sponsored by HistoSonics, a U-M spinoff company.

2022-04-17 - Scientists say they've partially destroyed liver tumours in rats ...

The human trial currently ongoing for histotripsy, called #HOPE4LIVER, is sponsored by HistoSonics, a company created by the University of Michigan.

2021-02-02 - HistoSonics Announces First Patient Treated in US Clinical Study of Novel Sonic Beam Therapy for Liver Tumors

MINNEAPOLIS, Feb. 2, 2021 /PRNewswire/ -- HistoSonics, developer of a non-invasive platform and novel sonic beam therapy, announced today the treatment of the first patient in the #HOPE4LIVER US Study. The investigational device study was approved by the FDA in the fourth quarter of 2020. The ...

2021-01-11 - HistoSonics Receives Approval To Begin European #HOPE4LIVER Clinical Study

MINNEAPOLIS, Jan. 11, 2021 /PRNewswire/ -- HistoSonics, developer of a non-invasive platform and novel sonic beam therapy, announced today that it has received approval to initiate the company's second European clinical trial of its new platform technology, which is designed to use the science ...

2020-10-05 - HistoSonics Announces Approval of its #HOPE4LIVER US Clinical Study

MINNEAPOLIS, Oct. 5, 2020 /PRNewswire/ -- HistoSonics, developer of a non-invasive platform and novel sonic beam therapy, announced today that it has received approval of an Investigational Device Exemption (IDE) from the U.S. Food and Drug Administration (FDA) to begin a clinical trial of its ...

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$35M14012%N/A
#2
$15M1414%N/A
#3
$23.6M143-2%N/A
#4
$33.3M144-9%N/A
#5
$53M1462%N/A